A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33)
Clinical trial NCT04317066 · COMPLETED
Trial details
- NCT number
- NCT04317066
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-26
- Primary completion
- 2024-04-11
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.